<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01856634</url>
  </required_header>
  <id_info>
    <org_study_id>242-12-232</org_study_id>
    <nct_id>NCT01856634</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic and Safety Trial to Determine the Appropriate Dose for Pediatric Patients With Multidrug Resistant Tuberculosis</brief_title>
  <official_title>Phase 1, Open-label, Multiple-dose, and Age De-escalation Trial to Assess the Pharmacokinetics, Safety and Tolerability of Delamanid (OPC 67683) in Pediatric Multidrug-resistant Tuberculosis Patients on Therapy With an Optimized Background Regimen of Anti-tuberculosis Drugs</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Otsuka Pharmaceutical Development &amp; Commercialization, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Otsuka Pharmaceutical Development &amp; Commercialization, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial is to determine the pediatric dose of delamanid that is equivalent
      to the adult dose already shown to be effective against multidrug-resistant tuberculosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This trial will investigate the pharmacokinetics (PK) and safety of delamanid administered
      for 10 days to pediatric patients aged birth to 17 years who are also on therapy with an
      optimized background regimen. The purpose of the trial is to determine which dose in
      pediatric MDR-TB patients will result in delamanid plasma exposure similar to efficacious
      plasma exposure in adult MDR-TB patients. This is an age de-escalation trial in four groups:

      Group 1: 12 to 17 years (100 mg BID; n=6) Group 2: 6 to 11 years (50 mg BID; n=6) Group 3: 3
      to 5 years (25 mg BID; n=12) Group 4: Birth to 2 years (Dose based on patient's body weight,
      n=12)

        -  Patients &gt; 10 kg will receive 10 mg BID

        -  Patients &gt; 8 kg and ≤ 10 kg will receive 5 mg BID

        -  Patient ≤ to 8 kg will receive 5 mg QD
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 14, 2013</start_date>
  <completion_date type="Actual">December 28, 2017</completion_date>
  <primary_completion_date type="Actual">December 10, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma Concentrations</measure>
    <time_frame>Days 1, 2, 10, 11, 13 (Groups 1 and 2 only), 15, 18</time_frame>
    <description>Plasma concentrations (Cmax, tmax, AUC 0-24h, accumulation ratio, apparent terminal elimination half-life, apparent total clearance) of delamanid and its metabolites on Days 1, 2, 10, 11, 13 (Groups 1 and 2 only), 15, 18.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>40 Days</time_frame>
    <description>Number of reported adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Summary</measure>
    <time_frame>40 Days</time_frame>
    <description>Summary statistics of subjects with clinically significant abnormal laboratory test results, vitals, ECGs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Palatability of the Pediatric Formulation</measure>
    <time_frame>Days 1 and 10</time_frame>
    <description>Palatability of the pediatric formulation will be assessed using an age-appropriate visual hedonic scale and clinical assessment for Groups 3 and 4 only.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">37</enrollment>
  <condition>Multidrug Resistant Tuberculosis</condition>
  <condition>Pediatric</condition>
  <arm_group>
    <arm_group_label>Group 1: 12 to 17 years of age</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 1: 100 mg Delamanid BID for 10 days + OBR</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: 6 to 11 years of age</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50 mg Delamanid BID for 10 days + OBR</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3: 3 to 5 years of age</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>25 mg Pediatric Formulation Delamanid BID for 10 days + OBR</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4: Birth to 2 years of age</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Delamanid Pediatric Formulation (DPF) for 10 days + OBR. DPF dose based on patient's body weight during baseline visit:
Patient's &gt; 10 kg will receive DPF 10 mg BID + OBR
Patient's &gt; 8 kg and ≤ 10 kg will receive DPF 5 mg BID + OBR
Patients ≤ 8 kg will receive DPF 5 mg QD + OBR</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>100 mg Delamanid</intervention_name>
    <description>100 mg Delamanid BID for 10 days</description>
    <arm_group_label>Group 1: 12 to 17 years of age</arm_group_label>
    <other_name>OPC-67683</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>50 mg Delamanid</intervention_name>
    <description>50 mg Delamanid BID for 10 days</description>
    <arm_group_label>Group 2: 6 to 11 years of age</arm_group_label>
    <other_name>OPC-67683</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>25 mg Pediatric Formulation Delamanid</intervention_name>
    <description>25 mg Pediatric Formulation Delamanid BID for 10 days</description>
    <arm_group_label>Group 3: 3 to 5 years of age</arm_group_label>
    <other_name>DPF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>10 mg Delamanid Pediatric Formulation</intervention_name>
    <description>Patients &gt; 10 kg will receive DPF 10 mg BID for 10 days</description>
    <arm_group_label>Group 4: Birth to 2 years of age</arm_group_label>
    <other_name>DPF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5 mg Delamanid Pediatric Formulation</intervention_name>
    <description>Patients &gt; 8 kg and ≤ 10 kg will receive DPF 5 mg BID for 10 days
Patients ≤ 8 kg will receive DPF 5 mg QD for 10 days</description>
    <arm_group_label>Group 4: Birth to 2 years of age</arm_group_label>
    <other_name>DPF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Optimized Background Regimen</intervention_name>
    <description>Selection and administration of the treatment medications (i.e. OBRs) will be based on WHO's Guidelines for the programmatic management of drug-resistant TB, in conjunction with national TB program guidelines in each country</description>
    <arm_group_label>Group 1: 12 to 17 years of age</arm_group_label>
    <arm_group_label>Group 2: 6 to 11 years of age</arm_group_label>
    <arm_group_label>Group 3: 3 to 5 years of age</arm_group_label>
    <arm_group_label>Group 4: Birth to 2 years of age</arm_group_label>
    <other_name>OBR</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed diagnosis of MDR-TB OR

          -  Presumptive diagnosis of MDR-TB including one of the following:

               -  Clinical specimen suggestive of TB

               -  Persistent cough lasting &gt; 2 weeks

               -  Fever, weight loss, and failure to thrive

               -  Findings on recent chest radiograph (prior to Visit 1) consistent with TB AND

               -  Household contact of a person with known MDR-TB or a person who died while
                  appropriately taking drugs for sensitive TB OR

               -  On first-line TB treatment but with no clinical improvement

          -  Negative urine pregnancy test for female patients who have reached menarche

          -  Written informed consent/assent

        Exclusion Criteria:

          -  Laboratory evidence of active hepatitis B or C

          -  Children with body weight &lt; 5.5 kg

          -  For patients with HIV co-infection, CD4 cell count ≤ 1000/mm3 for children 1-5 years
             old, and ≤ 1500/mm3 for children less than 1 year old

          -  History of allergy to metronidazole and any disease or condition in which
             metronidazole is required

          -  Use of amiodarone within 12 months or use of other predefined antiarrhythmic
             medications within 30 days prior to first dose of delamanid

          -  Serious concomitant conditions

          -  Preexisting cardiac conditions

          -  Abnormalities in Screening ECG (including AV block, BBB or hemi-block, QRS
             prolongation &gt; 120 msec, or QTcF &gt; 450 msec in both males and females)

          -  Concomitant condition such as renal impairment characterized by serum creatinine
             levels &gt;1.5 mg/dL, hepatic impairment (ALT or AST &gt; 3x ULN), or hyperbilirubinemia
             characterized by total bilirubin &gt; 2x ULN

          -  Current diagnosis of severe malnutrition or kwashiorkor

          -  Positive urine drug screen (Groups 1 and 2 only)

          -  Rifampicin and/or moxifloxacin within 1 week prior to the first dose of delamanid
             and/or any prior or concurrent use of bedaquiline

          -  Lansky Play Performance Score &lt; 50 (not applicable for children &lt; 1 year old) or
             Karnofsky Score &lt; 50

          -  Administered an IMP within 1 month prior to Visit 1

          -  Pregnant, breast-feeding, or planning to conceive or father a child within the
             timeframe described in the information consent form (Groups 1 and 2 only)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey Hafkin, MD</last_name>
    <role>Study Director</role>
    <affiliation>Otsuka Pharmaceutical Development &amp; Commercialization, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>De La Salle Health Sciences Institute</name>
      <address>
        <city>Dasmariñas</city>
        <state>Cavite</state>
        <zip>4114</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brooklyn Chest Hospital</name>
      <address>
        <city>Ysterplaat</city>
        <state>Cape Town</state>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Philippines</country>
    <country>South Africa</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 15, 2013</study_first_submitted>
  <study_first_submitted_qc>May 15, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 17, 2013</study_first_posted>
  <last_update_submitted>January 27, 2018</last_update_submitted>
  <last_update_submitted_qc>January 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 30, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tuberculosis</keyword>
  <keyword>Tuberculosis, Multidrug-Resistant</keyword>
  <keyword>Mycobacterium Infections</keyword>
  <keyword>Actinomycetales Infections</keyword>
  <keyword>Gram-Positive Infections</keyword>
  <keyword>Bacterial Infections</keyword>
  <keyword>Pediatric</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
    <mesh_term>Tuberculosis, Multidrug-Resistant</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

